XML 18 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities:      
Net loss $ (173,143) $ (97,591) $ (76,367)
Adjustments to reconcile net loss to net cash used for operating activities:      
Stock-based compensation expense 25,956 14,360 8,067
Depreciation and amortization 1,099 734 578
Amortization of Debt Discount (Premium) 689 624 573
Impairment loss on property and equipment 0 0 905
Loss (gain) on disposal of property and equipment 9 (118) 17
Amortization of premium on short-term investments 274 89
Change in operating assets and liabilities:      
Accounts receivable (1,960)
Prepaid expenses and other current assets (338) (2,443) (419)
Inventory (5,340)
Accounts payable 3,514 751 1,285
Accrued clinical liabilities 7,976 1,420 2,038
Accrued payroll and employee liabilities 3,586 2,097 165
Deferred revenue 1,099
Other accrued liabilities 2,482 1,551 2,876
Net cash used for operating activities (134,097) (78,526) (60,282)
Investing activities:      
Purchases of short-term investments (43,318) (56,115)
Maturities of short-term investments 61,329
Purchases of property and equipment (3,135) (1,086) (1,438)
Proceeds from the sale of property and equipment 241
Net cash provided by (used for) investing activities 14,876 (56,960) (1,438)
Financing activities:      
Net proceeds from sale of common stock and/or pre-funded warrants 128,199 58,916
Proceeds from purchases under the Employee Stock Purchase Plan 771 257 91
Proceeds from stock option exercises 6,684 9,535 3,101
Proceeds from issuance of promissory note payable to related party 50,000
Net cash provided by financing activities 57,455 137,991 62,108
Net (decrease) increase in cash and cash equivalents (61,766) 2,505 388
Cash and cash equivalents at beginning of year 75,180 72,675 72,287
Cash and cash equivalents at end of year 13,414 75,180 72,675
Supplemental disclosure of cash flow information:      
Interest paid $ 1,622